Results 191 to 200 of about 8,336,904 (303)

MDL‐800‐induced SIRT6 activation decreases age‐associated osteoarthritis in mice

Arthritis &Rheumatology, Accepted Article.
Objective SIRT6 is a nuclear‐localized histone deacetylase that regulates multiple pathways associated with aging. This study aimed to determine whether systemic administration of a small molecule activator of SIRT6, MDL‐800, decreases the severity of age‐associated osteoarthritis (OA) in mice.
Matheus Moreira Perez, Pranay Ramteke, Bahiyah Watson, Owen Haslam, Eirene Choi, Susan Chubinskaya, Mandy J. Peffers, William R. Davis, Jacqueline Shine, Brian O. Diekman, Richard F. Loeser, Theresa A. Freeman, Makarand V. Risbud, John A. Collins   +13 more
wiley   +1 more source

Human Leukocyte Antigen-G is enriched in presence of trypanosome in the dermis of individuals exposed to gambiense Human African Trypanosomiasis in Guinea and Côte d'Ivoire. [PDF]

PLoS Negl Trop Dis
Lagrave A, Camara A, Gineau L, Tichit M, Gnankou FB, Soumah AM, Camara M, N'Djetchi M, Kaboré JW, Camara O, Coulibaly B, Sépé B, Nanan V, Kouadio KAM, N'Dri L, Konan T, Milet J, Boiro S, Travaillé C, Crouzols A, Petiot N, Ilboudo H, Hardy D, Sadissou I, Bart JM, Camara M, Kaba D, Koffi M, Bucheton B, Jamonneau V, Courtin D, Rotureau B.   +31 more
europepmc   +1 more source

Early Diagnosis of Axial Spondyloarthritis Is Associated With Less Long‐Term Spinal Structural Damage: A Longitudinal Analysis of the Swiss Clinical Quality Management in Rheumatic Diseases Registry

Arthritis &Rheumatology, EarlyView.
Objective The Assessment of SpondyloArthritis international Society recently defined early axial spondyloarthritis (axSpA) as a duration of two years or less of axial symptoms. Previous studies have shown no significant difference in short‐term outcomes between patients with early and established axSpA treated with biologic/targeted synthetic disease ...
Annik Steimer, Jonas Brändli, Mauro Bachmann, Andrea Götschi, Claudia L. Rodrigues, Michael J. Nissen, Burkhard Möller, Kristina Bürki, Martin Wendiggensen, Simon Grosswiler, Michael Andor, Diana Dan, Frauke Förger, Sabine Adler, Diego Kyburz, Oliver Distler, Raphael Micheroli, Sofia Ramiro, Adrian Ciurea   +18 more
wiley   +1 more source

Human Leukocyte Antigen (<i>HLA</i>) Signatures and Idiosyncratic Drug-Induced Liver Injury. [PDF]

Int J Mol Sci
Onaciu A, Grama A, Agoșton Ș, Mititelu A, Mariş B, Ştefănescu H, Pop TL.   +6 more
europepmc   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Prediction of KIR3DL1 and human leukocyte antigen binding. [PDF]

J Biol Chem
Maiers M, Louzoun Y, Pymm P, Vivian JP, Rossjohn J, Brooks AG, Saunders PM.   +6 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Gut bacterial and fungal signatures in relation to human leukocyte antigen-DQ2/DQ8 in children with celiac disease and siblings. [PDF]

World J Gastroenterol
Salamon D, Krawczyk A, Zapała B, Duplaga M, Kowalska-Duplaga K, Gosiewski T.   +5 more
europepmc   +1 more source

A future without human leukocyte antigens?

Hematology, Transfusion and Cell Therapy, 2018
openaire   +3 more sources

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source